Hereditary angioedema (HAE) is a genetic disorder that causes episodes of extreme swelling (angioedema), commonly in the face, hands, feet, digestive tract, or upper airways. Symptoms may begin ...

6 Hereditary angioedema typically presents as recurrent episodes of nonpitting, nonpruritic edema affecting 3 main areas: subcutaneous tissue (face, upper or lower extremities, genitals ...

Angioedema Control Test Scores rose from 11.3 to 13.9. The percentage of patients with well-controlled disease rose from 67% to 93%. SAN DIEGO — Patients with hereditary angioedema who switched ...

Hereditary angioedema is characterized by unpredictable swelling involving the face, oropharynx, extremities, or abdomen, without hives or pruritus. Laryngeal attacks carry a risk of asphyxiation, ...

The company is on track to complete enrollment in the global Phase 3 HAELO study for hereditary angioedema (HAE) by the third quarter of 2025 and has dosed the first patient in the Phase 3 ...

Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but its ...

Takhzyro (lanadelumab-flyo) is a prescription drug that’s used to help prevent attacks of hereditary angioedema (HAE). Takhzyro comes as a subcutaneous injection. Takhzyro is used to help ...

BioCryst Pharma's Orladeyo has been recommended by NICE as a treatment for the rare disease hereditary angioedema (HAE) in England, Wales and Northern Ireland. Orladeyo (berotralstat ...

KalVista's lead asset, sebetralstat, is nearing FDA approval, targeting hereditary angioedema with a first-in-class oral treatment, presenting a significant market opportunity. Strong financial ...

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Firazyr Injection, 30 mg/3 mL (10 mg/mL), of Takeda Pharmaceuticals USA, Inc, it added. Get updates on ...